Advertisement

Orthopädie & Rheuma

, Volume 21, Issue 6, pp 21–25 | Cite as

Eine interdisziplinäre Aufgabe

Konservative Behandlungsoptionen bei Spastik

  • Marcela Lippert-Grüner
  • Axel Schulz
  • Stephan Grüner
Fortbildung
  • 15 Downloads

Spastik ist ein Symptom, das nicht nur in der Neurologie, sondern in allen Fachgebieten mit Beteiligung des Stütz-und Bewegungsapparats anzutreffen ist. Neben der gestörten Muskelfunktion geht es auch mit sekundären Schäden am Bewegungsapparat und Schmerzen einher. Diese Übersichtsarbeit informiert über die Grundlagen, die Diagnostik, die Epidemiologie und die Behandlungsmöglichkeiten der Spastik.

Literatur

  1. 1.
    Dietz V. Spastic movement disorder. Spinal Cord 2000; 38(7): 389–93PubMedPubMedCentralGoogle Scholar
  2. 2.
    Hyman N, Barnes M, Bhakta B, Cozens A, Bakheit M, Kreczy-Kleedorfer B, Poewe W, Wissel J, Bain P, Glickman S, Sayer A, Richardson A, Dott C. Botulinum toxin (Dysport) treatment of hip adductor spasticity in multiple sclerosis: a prospective, randomised, double blind, placebo controlled, dose ranging study. J Neurol Neurosurg Psychiatry 2000; 68(6): 707–12PubMedPubMedCentralGoogle Scholar
  3. 3.
    Bohannon RW, Smith MB. Interrater reliability of a modified Ashworth scale of muscle spasticity. Phys Ther 1987; 67(2): 206–7PubMedPubMedCentralGoogle Scholar
  4. 4.
    Platz T, Vuadens P, Eickhof C, Arnold P, Van Kaick S, Heise K. REPAS, a summary rating scale for resistance to passive movement: item selection, reliability and validity. Disabil Rehabil 2008; 30(1): 44–53PubMedPubMedCentralGoogle Scholar
  5. 5.
    Sommerfeld DK, Eek EU, Svenson AK, Holmqvist LW, von Arbin MH. Spasticity after stroke: its occurrence and association with motor impairments and activity limitations. Stroke 2004; 35(1): 134–9PubMedPubMedCentralGoogle Scholar
  6. 6.
    Ward A, Chaffman MO, Sorkin EM. Dantrolene. A review of its pharmacodynamics and pharmacokinetic properties and therapeutic use in malignant hyperthermia, the neuroleptic malignant syndrome and an update of its use in muscle spasticity. Drugs 1986; 32(2): 130–68PubMedPubMedCentralGoogle Scholar
  7. 7.
    Welmer AK, Widen Holmqvist L, Sommerfeld DK. Location and severity of spasticity in the first 1-2 weeks and at 3 and 18 months after stroke. Eur J Neurol 2010; 17(5): 720–5PubMedPubMedCentralGoogle Scholar
  8. 8.
    Winter Th, Wissel J. Behandlung der Spastizität nach Schlaganfall. Neurol Rehabil 2013; 19(5): 285–309Google Scholar
  9. 9.
    Kauhanen S, Leivo I, Michelsson JE. Early muscle changes after immobilisation. An experimental study of muscle damage. Clin Orthop Relat Res 1993; 297: 44–50Google Scholar
  10. 10.
    Gottschling S, Müller S, Theurer J, Bialas P, Ebinger F, Meyer S, Gronwald, B. Dronabinol bei schwerst-mehrfach-behinderten Kindern mit Spastik, Schmerzen und Unruhe. Z Palliativmed 2014: 15(3): PD356Google Scholar
  11. 11.
    Nauck F, Klaschik E. Dronabinol (deltag-tetrahydrocannabinol) in der Langzeittherapie. Symptomkontrolle bei multipler Sklerose mit Spastik, neuropathischen Schmerzen, Appetitlosigkeit und Kachexie. Schmerz 2004; 18 Suppl 2, S26–30PubMedPubMedCentralGoogle Scholar
  12. 12.
    Landa L, Jurica J, Sliva J, Pechackova M, Demlova R. Medical cannabis in the treatment of cancer pain and spastic conditions and options of drug delivery in clinical practice. Biomed Pap Med Fac Univ Palacky Olomouc Czech Repub 2018; 162(1), 18–25PubMedPubMedCentralGoogle Scholar
  13. 13.
    Childers MK, Brashear A, Jozefczyk P, Reding M, Alexander D, Good D, Walcott JM, Jenkins SW, Turkel C, Molly PT. Dose-dependent Response to intramuscular botulinum toxin type A for upper-limb spasticity in patients after a stroke. Arch Phys Med Rehabil 2004; 85(7): 1063–9PubMedPubMedCentralGoogle Scholar
  14. 14.
    Yablon SA, Brin MF, VanDenburgh AM, Zhou J, Garabedian-Ruffalo SM, Abu-Shakra S, Beddingfield FC. Dose response with onabotulinumtoxinA for post-stroke spasticity: a pooled data analysis. Mov Disord 2011; 26(2): 209–15PubMedPubMedCentralGoogle Scholar
  15. 15.
    Pittock SJ, Moore AP, Hardiman O, Ehler E, Kovac M, Bojakowski J, Al Khawaja I, Brozman M. Kanovsky P, Skorometz A, Slawek J, Reichel G, Stenner A, Timerbaeva S, Stelmasiak Z, Zifko UA, Bhakta B, Coxon E. A double-blind randomised placebo-controlled evaluation of three doses of botulinum toxin type A (Dysport) in the treatment of spastic equinovarus deformity after stroke. Cerebrovasc Dis 2003; 15(4): 289–300PubMedPubMedCentralGoogle Scholar
  16. 16.
    Messner M, Ceballos-Baumann A. Therapie der fokalen Spastik mit Botulinumtoxin. Nervenheilkunde 2018; 27(12): 1109–16Google Scholar
  17. 17.
    Wissel J, Muller J, Dressnandt J, Heinen F, Naumann M, Topka H, Poewe W. Management of spasticity associated pain with botulinum toxin A. J Pain Symptom Manage 2000; 20(1): 44–9PubMedPubMedCentralGoogle Scholar
  18. 18.
    Lim JY, Koh JH, Paik NJ. Intramuscular botulinum toxin-A reduces hemiplegic shoulder pain: a randomized, double-blind, comparative study versus intraarticular triamcinolone acetonide. Stroke 2008; 39(1): 126–131PubMedGoogle Scholar
  19. 19.
    Chalkiadaki A, Rohr UP, Hefter H. Frühe Schmerzreduktion in der Therapie von Spastik nach einmaliger Botulinustoxin-A-Injektion. Dtsch Med Wochensch 2001; 126(48): 1361–4Google Scholar
  20. 20.
    Sommer C, Üçeyler N. Botulinumtoxin zur Behandlung von neuropathischen Schmerzen. Nervenheilkunde 2018; 36(05): 315–23Google Scholar
  21. 21.
    Erbguth FJ. Ungewöhnliche therapeutische Anwendungen von Botulinumtoxin. Aktuelle Neurologie 2015; 42(02): 105–11Google Scholar
  22. 22.
    Aoki KR, Francis J, Jost WH. Mögliche antinozizeptive Mechanismen von Botulinumtoxin. Schmerz 2006; 20: 381–87PubMedPubMedCentralGoogle Scholar
  23. 23.
    Gazerani P, Pedersen NS, Staahl C, Drewes AM, Arendt-Nielsen, L. Subcutaneous Botulinum toxin type A reduces capsaicin-induced trigeminal pain and vasomotor reactions in human skin. Pain 2009; 141(1-2): 60–9PubMedPubMedCentralGoogle Scholar
  24. 24.
    Krämer HH, Angerer C, Erbguth F, Schmelz M, Birklein F. Botulinum Toxin A reduces neurogenic flare but has almost no effect on pain and hyperalgesia in human skin. J Neurol 2003; 250(2): 188–93PubMedPubMedCentralGoogle Scholar
  25. 25.
    Ranoux D, Attal N, Morain F, Bouhassira D. Botulinum toxin type A induces direct analgesic effects in chronic neuropathic pain. Ann Neurol 2008; 64(3): 274–83PubMedPubMedCentralGoogle Scholar
  26. 26.
    Namazi H. Botulinum toxin type-A therapy in cluster headache: a novel molecular mechanism. J Headache Pain 2008; 9(2): 133PubMedPubMedCentralGoogle Scholar
  27. 27.
    Sostak P, Krause P, Förderreuther S, Reinisch, V, Straube A. Botulinum toxin type-A therapy in cluster headache: an open study. J Headache Pain 2007; 8(4): 236–41PubMedPubMedCentralGoogle Scholar
  28. 28.
    Zabalza RJ. Sustained response to botulinum toxin in SUNCT syndrome. Cephalalgia 2012; 32(11): 869–72PubMedPubMedCentralGoogle Scholar
  29. 29.
    Yuan RY, Sheu JJ, Yu JM, Chen WT, Tseng IJ, Chang HH, Hu CJ. Botulinum toxin for diabetic neuropathic pain: a randomized double-blind crossover trial. Neurology 2009; 72(17): 1473–8PubMedPubMedCentralGoogle Scholar
  30. 30.
    Xiao L, Mackey S, Hui H, Xong D, Zhang Q, Zhang D. Subcutaneous injection of botulinum toxin a is beneficial in postherpetic neuralgia. Pain Med 2010; 11(12): 1827–33PubMedPubMedCentralGoogle Scholar
  31. 31.
    Wu C-J, Lian Y-J, Zheng Y-K, Zhang, H-F, Chen, Y, Xie N-C, Wang L-J. Botulinum toxin type A for the treatment of trigeminal neuralgia: results from a randomized, double-blind, placebo-controlled trial. Cephalalgia 2012; 32(6): 443–50PubMedPubMedCentralGoogle Scholar
  32. 32.
    Jin L, Kollewe K, Krampfl K, Dengler R, Mohammadi B. Treatment of phantom limb pain with botulinum toxin type A. Pain Med 2009; 10(2): 300–3PubMedPubMedCentralGoogle Scholar
  33. 33.
    Sheean G. Botulinum Toxin Treatment of Adult Spasticity: a benefit-risk assessment. Drug Saf 2006; 29(1): 31–48PubMedPubMedCentralGoogle Scholar
  34. 34.
    Gordon MF, Brashear A, Elovic E, Kassicieh D, Marciniak C, Liu J, Turkel C. Repeated dosing of botulinum toxin type A for upper limb spasticity following stroke. Neurology 2004; 63(10): 1971–3PubMedPubMedCentralGoogle Scholar
  35. 35.
    Mohammadi B, Balouch SA, Dengler R, Kollewe K. Long-term treatment of spasticity with botulinum toxin type A: an analysis of 1221 treatments in 137 patients. Neurol Res 2010; 32(3): 309–13PubMedPubMedCentralGoogle Scholar
  36. 36.
    Bakheit AM, Thilmann AF, Ward AB, Poewe W, Wissel J, Muller J, Benecke R, Collin C, Muller F, Ward CD, Neumann C. A randomized, double-blind, placebo-controlled, dose-ranging study to compare the efficacy and safety of three doses of botulinum toxin type A (Dysport) with placebo in upper limb spasticity after stroke. Stroke 2000; 31(10): 2402–6PubMedPubMedCentralGoogle Scholar
  37. 37.
    Yablon SA, Brashear A, Gordon MF, Elovic EP, Turkel CC, Daggett S, Liu J, Brin MF. Formation of neutralizing antibodies in patients receiving botulinum toxin type A for treatment of poststroke spasticity: a pooled data analysis of three clinical trials. Clin Ther 2007; 29(4): 683–90Google Scholar
  38. 38.
    Hesse S, Jahnke MT, Luecke D, Mauritz KH: Short-term electrical stimulation enhances the effectiveness of Botulinum toxin in the treatment of lower limb spasticity in hemiparetic patients. Neurosci Lett 1995; 201(1): 37–40PubMedPubMedCentralGoogle Scholar
  39. 39.
    Reiter F, Danni M, Lagalla G, Ceravolo G, Provinciali L. Low-dose botulinum toxin with ankle taping for the treatment of spastic equinovarus foot after stroke. Arch Phys Med Rehabil 1998; 79(5): 532–5PubMedPubMedCentralGoogle Scholar
  40. 40.
    Schulz A, Grüner S, Lippert-Grüner M. Botulinumtoxin — mögliche Indikationen in O & U. OUP 2016; 5(4): 218–21Google Scholar

Copyright information

© Springer Medizin Verlag GmbH, ein Teil von Springer Nature 2018

Authors and Affiliations

  • Marcela Lippert-Grüner
    • 1
  • Axel Schulz
    • 2
  • Stephan Grüner
    • 3
    • 4
  1. 1.Klinik für Rehabilitationsmedizin, 3. Medizinische Fakultät Karlsuniversität PragFakultätskrankenhaus Královské VinohradyPraha 10Tschechische Republik
  2. 2.LüdenscheidDeutschland
  3. 3.Orthopädische Praxen Dr. GrünerKölnDeutschland
  4. 4.KölnDeutschland

Personalised recommendations